Loading…
Loading…
This MannKind insider filing details the disposition of 46,795 shares. The transaction reduced the insider's direct equity holdings by 9%.
The transactions involved 76,880 shares with a total value of about $313,000, based on a weighted average execution price of $4.07 per share. The disposition represented 9% of direct common stock holdings, which included shares delivered upon the recent vesting of performance-based awards.
David Thomson disposed of 123,000 shares at $4.08 per share, representing a total transaction value of about $500,000. The activity resulted in a 13% decrease in direct common stock holdings, which included shares recently acquired through the exercise of derivative securities.
This filing reported an insider's total disposition of 65,808 shares for an estimated value of $269,000 based on the July 15, 2026 market close. The transaction represented 6% of the insider's total direct common stock holdings.
The disposition involved ~363,000 shares valued at ~$1.5 million as of the July 15, 2026 transaction date. The activity represents 13% of the executive's direct equity holdings in the company.
Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use
Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes New data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfaction Exploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithms Data from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes DANBURY, Conn.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for MNKD and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.